Group managing director Leonard Ariff Abdul Shatar said the HAPI plant would produce various oncology drugs that were clinically proven to fight against many types of cancers.
KUALA LUMPUR: Pharmaceutical firm Duopharma Biotech Bhd, through wholly-owned subsidiary Duopharma HAPI Sdn Bhd, will soon manufacture its second oncology drug at its first-in-Malaysia highly potent active pharmaceutical ingredient (HAPI) Plant in Shah Alam to help address the paucity of affordable alternatives to treat cancer.
Group managing director Leonard Ariff Abdul Shatar said the HAPI plant would produce various oncology drugs that were clinically proven to fight against many types of cancers.
The HAPI plant is equipped to produce a wide portfolio of cancer medicines to help to treat, among others, breast cancer, lung cancer, colorectal cancer, cervical cancer, and blood cancer, making it the first cancer medicine manufacturing facility in Malaysia.
Duopharma Biotech group is embracing innovation and technology to serve patients who need specific and targeted therapies that can be produced by our new state-of-the-art HAPI Plant, he said in a statement to Bernama today.
The facility is also fully capable of producing medicines to treat hormonal imbalance and highly potent medicines for cardiovascular, central nervous system and musculoskeletal diseases. In the first quarter of this year, Duopharma Biotech successfully manufactured and commercialised its first product (letrozole), which is prescribed for breast cancer treatment.
Leonard Ariff revealed that the HAPI plant’s next product would be the first locally manufactured drug to treat chronic myeloid leukemia for both adults and children.
"The medicine which will be produced locally is targeted to be commercialised in due course,” he said.
This medicine produced at the HAPI plant, which is available at an affordable price, will enable patients especially in the low and middle income categories to have access to the treatment.
"Affordability and access issues are especially prevalent amongst the financially challenged and there is evidence that out-of-pocket costs for such prescription drugs to treat chronic diseases not only impose a financial burden but result in reduction in medication adherence leading to worsening health outcomes.
"Our objective in establishing the HAPI plant in Malaysia is premised on a mission to offer medication to address the lack of alternatives while delivering equitable and affordable access to prescription medications. The plant will also provide some level of self-sufficiency to the country in terms of the specific oncology medications,” he said.
The HAPI facility is a Good Manufacturing Practice certified plant by the Malaysian National Pharmaceutical Regulatory Agency (NPRA). This ensures that production and quality control consistently meet the highest standards.
Duopharma Biotech is also currently engaging with pharmaceutical companies across the globe to bring high-end technologies and allowing for technology transfer which enables it to locally manufacture high-value drugs.
This is expected to further strengthen the company’s position as the leading pharmaceutical player in Malaysia, and help it achieve its target of being a leading pharmaceutical company in Southeast Asia.
"We are widening our product portfolio by offering not just oncology medicines but also psychotropic drugs, which is an emerging market in Malaysia.
"Duopharma Biotech has already established a strong presence in the anti-psychotic sector and is collaborating with our partners to bring in more locally manufactured psychotropic drugs into our pipelines due to their huge market potential,” he added. - Bernama
Singapore Investment
-
-
-
-
-
🇬🇷 Ελληνικές μετοχές12 hours ago
-
-
-
-
5 simple tips to spend money more wisely22 hours ago
-
-
-
-
-
-
-
-
-
-
-
-
-
Will I be rich?2 days ago
-
-
-
-
-
-
Finance Investment Movement 593 days ago
-
-
-
-
-
Bird Paradise – at a discount3 days ago
-
-
-
-
-
-
-
-
-
-
-
Buying more1 week ago
-
-
-
-
-
I have Achieved Lean FIRE!!1 week ago
-
-
-
The Art of Being Patient2 weeks ago
-
-
-
-
-
2Q 2025 Investment Strategy Update2 weeks ago
-
Portfolio Summary for June 20252 weeks ago
-
-
Portfolio (June 30, 2025)2 weeks ago
-
Portfolio (June 30, 2025)2 weeks ago
-
-
-
Portfolio -- June 20252 weeks ago
-
June 2025 Updates2 weeks ago
-
-
-
Will SORA crash to 1 per cent?3 weeks ago
-
-
Hello world!3 weeks ago
-
-
-
8 tips for house moving4 weeks ago
-
-
-
-
-
-
-
-
-
-
-
Thakral - Gem life deal finally coming?1 month ago
-
-
-
Clarity1 month ago
-
The Trump Tariffs2 months ago
-
Selling HRnet and Fiverr2 months ago
-
-
-
-
Ignore the noise and be calm2 months ago
-
-
-
-
FAQ on Quantitative Investing Part 23 months ago
-
-
-
-
Crossing the 300k Mark [in a volatile period]3 months ago
-
-
-
-
-
-
-
-
ETF vs Mutual Fund: Which is Better?5 months ago
-
-
-
-
-
Arigato Everyone! A Decade of Blogging!6 months ago
-
Top 10 Highlights of 20246 months ago
-
-
-
Union Square Residences8 months ago
-
-
-
STI ETF9 months ago
-
-
-
Unibet Casino Bonus Codes 202410 months ago
-
-
-
-
-
Monthly IBKR Update – June 20241 year ago
-
-
-
-
-
-
-
-
-
Feb 2024 Expenditure1 year ago
-
-
-
-
-
-
-
Monthly Summary of November 20231 year ago
-
Migration of website1 year ago
-
-
-
-
-
-
Hello SP Group, I'm Back!2 years ago
-
-
-
A New Light2 years ago
-
-
-
-
-
2022 Thoughts, Hello 2023!2 years ago
-
Series of Defaults for Maple Finance2 years ago
-
Takeaways from “Sea Change”2 years ago
-
Greed is Coming Back2 years ago
-
-
-
-
-
-
-
-
What is Overemployment3 years ago
-
Terra Hill Condo (former Flynn Park)3 years ago
-
Alibaba VS Tencent: The Battle Royale3 years ago
-
-
-
-
-
-
-
-
-
-
-
-
-